NCT00550238

Brief Summary

To assess the long-term safety and tolerability of ACP-103 in subjects with Parkinson's disease psychosis.

Trial Health

98
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Strong global presence with extensive site network
Enrollment
459

participants targeted

Target at P50-P75 for phase_3

Timeline
Completed

Started Jul 2007

Longer than P75 for phase_3

Geographic Reach
13 countries

133 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 1, 2007

Completed
4 months until next milestone

First Submitted

Initial submission to the registry

October 26, 2007

Completed
3 days until next milestone

First Posted

Study publicly available on registry

October 29, 2007

Completed
10.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 30, 2018

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 30, 2018

Completed
1.1 years until next milestone

Results Posted

Study results publicly available

June 24, 2019

Completed
Last Updated

June 24, 2019

Status Verified

May 1, 2019

Enrollment Period

10.9 years

First QC Date

October 26, 2007

Results QC Date

May 29, 2019

Last Update Submit

May 29, 2019

Conditions

Keywords

Parkinson's Disease Psychosis

Outcome Measures

Primary Outcomes (1)

  • Safety: Number (%) of Patients With Drug-related Treatment-emergent Adverse Events (AEs)

    Number (%) of patients with drug-related treatment-emergent AEs (i.e. AEs reported by the Investigator as possibly, probably, or highly probably related to study drug)

    From first to last study drug dose plus 30 days

Study Arms (1)

Pimavanserin tartrate (ACP-103)

EXPERIMENTAL

Tablets taken once daily by mouth for as long as ACP-103 is considered to be tolerated and beneficial to subjects

Drug: Pimavanserin tartrate (ACP-103)

Interventions

Tablets taken once daily by mouth for as long as ACP-103 is considered to be tolerated and beneficial to subjects

Pimavanserin tartrate (ACP-103)

Eligibility Criteria

Age40 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Subject has completed the treatment period of a previous blinded study of pimavanserin
  • The subject is willing and able to provide consent
  • Caregiver is willing and able to accompany the subject to all visits

You may not qualify if:

  • Subject has current evidence of a serious and or unstable cardiovascular, respiratory, gastrointestinal, renal, hematologic or other medical disorder
  • Subject is judged by the Investigator to be inappropriate for the study

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (135)

Unknown Facility

Gilbert, Arizona, 85234, United States

Location

Unknown Facility

Phoenix, Arizona, 85013, United States

Location

Unknown Facility

Tucson, Arizona, 84724, United States

Location

Unknown Facility

Berkeley, California, 94705, United States

Location

Unknown Facility

Carson, California, 90746, United States

Location

Unknown Facility

Fountain Valley, California, 92708, United States

Location

Unknown Facility

Fresno, California, 93720, United States

Location

Unknown Facility

Irvine, California, 92697, United States

Location

Unknown Facility

La Habra, California, 90631, United States

Location

Unknown Facility

La Jolla, California, 92037, United States

Location

Unknown Facility

Laguna Hills, California, 92653, United States

Location

Unknown Facility

Loma Linda, California, 92354, United States

Location

Unknown Facility

Oxnard, California, 93030, United States

Location

Unknown Facility

Pasadena, California, 91105, United States

Location

Unknown Facility

Reseda, California, 91335, United States

Location

Unknown Facility

Sunnyvale, California, 94085, United States

Location

Unknown Facility

Ventura, California, 93003, United States

Location

Unknown Facility

Englewood, Colorado, 80113, United States

Location

Unknown Facility

Danbury, Connecticut, 06810, United States

Location

Unknown Facility

Fairfield, Connecticut, 06824, United States

Location

Unknown Facility

Farmington, Connecticut, 06030, United States

Location

Unknown Facility

Boca Raton, Florida, 33486, United States

Location

Unknown Facility

Bradenton, Florida, 34205, United States

Location

Unknown Facility

Deerfield Beach, Florida, 33064, United States

Location

Unknown Facility

Gainesville, Florida, 32610, United States

Location

Unknown Facility

Jacksonville, Florida, 32209, United States

Location

Unknown Facility

Miami, Florida, 33136, United States

Location

Unknown Facility

Naples, Florida, 34102, United States

Location

Unknown Facility

Orlando, Florida, 32806, United States

Location

Unknown Facility

Ormond Beach, Florida, 32174, United States

Location

Unknown Facility

Panama City, Florida, 32405, United States

Location

Unknown Facility

Pompano Beach, Florida, 33060, United States

Location

Unknown Facility

Port Charlotte, Florida, 33980, United States

Location

Unknown Facility

Sarasota, Florida, 34233, United States

Location

Unknown Facility

St. Petersburg, Florida, 33701, United States

Location

Unknown Facility

Tampa, Florida, 33606, United States

Location

Unknown Facility

Augusta, Georgia, 30912, United States

Location

Unknown Facility

Decatur, Georgia, 30033, United States

Location

Unknown Facility

Glenview, Illinois, 60026, United States

Location

Unknown Facility

Springfield, Illinois, 62794, United States

Location

Unknown Facility

Kansas City, Kansas, 66160, United States

Location

Unknown Facility

Louisville, Kentucky, 40202, United States

Location

Unknown Facility

Scarborough, Maine, 04074, United States

Location

Unknown Facility

Baltimore, Maryland, 21287, United States

Location

Unknown Facility

Boston, Massachusetts, 02215, United States

Location

Unknown Facility

Worcester, Massachusetts, 01655, United States

Location

Unknown Facility

Clinton Township, Michigan, 48037, United States

Location

Unknown Facility

Detroit, Michigan, 48201, United States

Location

Unknown Facility

East Lansing, Michigan, 48824, United States

Location

Unknown Facility

Roseville, Michigan, 48066, United States

Location

Unknown Facility

Traverse City, Michigan, 49684, United States

Location

Unknown Facility

West Bloomfield, Michigan, 48334, United States

Location

Unknown Facility

Columbia, Missouri, 65201, United States

Location

Unknown Facility

St Louis, Missouri, 63110, United States

Location

Unknown Facility

Missoula, Montana, 59802, United States

Location

Unknown Facility

Toms River, New Jersey, 08755, United States

Location

Unknown Facility

Albany, New York, 12208, United States

Location

Unknown Facility

Commack, New York, 11725, United States

Location

Unknown Facility

Kingston, New York, 12401, United States

Location

Unknown Facility

Rochester, New York, 14618, United States

Location

Unknown Facility

Asheville, North Carolina, 28806, United States

Location

Unknown Facility

Charlotte, North Carolina, 28204, United States

Location

Unknown Facility

Durham, North Carolina, 27705, United States

Location

Unknown Facility

New Bern, North Carolina, 28562, United States

Location

Unknown Facility

Salisbury, North Carolina, 28144, United States

Location

Unknown Facility

Cincinnati, Ohio, 45210, United States

Location

Unknown Facility

Cleveland, Ohio, 44195, United States

Location

Unknown Facility

Columbus, Ohio, 43210, United States

Location

Unknown Facility

Toledo, Ohio, 43614, United States

Location

Unknown Facility

Greensburg, Pennsylvania, 15601, United States

Location

Unknown Facility

Philadelphia, Pennsylvania, 19131, United States

Location

Unknown Facility

Providence, Rhode Island, 02906, United States

Location

Unknown Facility

Brentwood, Tennessee, 37027, United States

Location

Unknown Facility

Houston, Texas, 77030, United States

Location

Unknown Facility

Salt Lake City, Utah, 84108, United States

Location

Unknown Facility

Burlington, Vermont, 05401, United States

Location

Unknown Facility

Alexandria, Virginia, 22311, United States

Location

Unknown Facility

Richmond, Virginia, 23229, United States

Location

Unknown Facility

Roanoke, Virginia, 24018, United States

Location

Unknown Facility

Virginia Beach, Virginia, 23456, United States

Location

Unknown Facility

Kirkland, Washington, 98034, United States

Location

Unknown Facility

Spokane, Washington, 99204, United States

Location

Unknown Facility

Milwaukee, Wisconsin, 53233, United States

Location

Unknown Facility

Innsbruck, 6020, Austria

Location

Unknown Facility

Vienna, 1090, Austria

Location

Unknown Facility

Roeselare, 8800, Belgium

Location

Unknown Facility

London, Ontario, N6A 5A5, Canada

Location

Unknown Facility

Ottawa, Ontario, K1G 4G3, Canada

Location

Unknown Facility

Clermont-Ferrand, 63003, France

Location

Unknown Facility

Marseille, 13385, France

Location

Unknown Facility

Nantes, 44093, France

Location

Unknown Facility

Pessac, 33604, France

Location

Unknown Facility

Strasbourg, 67091, France

Location

Unknown Facility

Bangalore, 560 034, India

Location

Unknown Facility

Chennai, 600 006, India

Location

Unknown Facility

Hyderabad, 500003, India

Location

Unknown Facility

Madurai, 625 020, India

Location

Unknown Facility

Mangalore, 575 001, India

Location

Unknown Facility

Mangalore, 575 002, India

Location

Unknown Facility

Mumbai, 400 016, India

Location

Unknown Facility

Mumbai, 400 026, India

Location

Unknown Facility

Pune, 411 004, India

Location

Unknown Facility

Pune, 411 030, India

Location

Unknown Facility

Visakhapatnam, 530 002, India

Location

Unknown Facility

Chieti, 66013, Italy

Location

Unknown Facility

Grosseto, 58100, Italy

Location

Unknown Facility

Rome, 00163, Italy

Location

Unknown Facility

Rome, 00185, Italy

Location

Unknown Facility

Bydgoszcz, 85796, Poland

Location

Unknown Facility

Katowice, 40-752, Poland

Location

Unknown Facility

Lublin, 20-090, Poland

Location

Unknown Facility

Coimbra, 3000-548, Portugal

Location

Unknown Facility

Lisbon, 1649-028, Portugal

Location

Unknown Facility

Porto, 4099-001, Portugal

Location

Unknown Facility

Kazan', 420061, Russia

Location

Unknown Facility

Kirov, 610014, Russia

Location

Unknown Facility

Moscow, 125284, Russia

Location

Unknown Facility

Pyatigorsk, 357538, Russia

Location

Unknown Facility

Saint Petersburg, 194044, Russia

Location

Unknown Facility

Samara, 443095, Russia

Location

Unknown Facility

Smolensk, 214018, Russia

Location

Unknown Facility

Belgrade, 11000, Serbia

Location

Unknown Facility

Novi Sad, 21000, Serbia

Location

Unknown Facility

Stockholm, SE-112 45, Sweden

Location

Unknown Facility

Kharkiv, 61068, Ukraine

Location

Unknown Facility

Kiev, 04080, Ukraine

Location

Unknown Facility

Kiev, 04114, Ukraine

Location

Unknown Facility

Luhansk, 91045, Ukraine

Location

Unknown Facility

Lviv, 79010, Ukraine

Location

Unknown Facility

Vinnitsia, 21005, Ukraine

Location

Unknown Facility

Barnsley, S75 2EP, United Kingdom

Location

Unknown Facility

Blackburn, BB2 3HH, United Kingdom

Location

Unknown Facility

London, NW3 20G, United Kingdom

Location

Unknown Facility

Newcastle, NE4 6BE, United Kingdom

Location

Unknown Facility

North Shields, NE21 8NH, United Kingdom

Location

Related Publications (2)

  • Mathis MV, Muoio BM, Andreason P, Avila AM, Farchione T, Atrakchi A, Temple RJ. The US Food and Drug Administration's Perspective on the New Antipsychotic Pimavanserin. J Clin Psychiatry. 2017 Jun;78(6):e668-e673. doi: 10.4088/JCP.16r11119.

    PMID: 28493654BACKGROUND
  • Ballard C, Isaacson S, Mills R, Williams H, Corbett A, Coate B, Pahwa R, Rascol O, Burn DJ. Impact of Current Antipsychotic Medications on Comparative Mortality and Adverse Events in People With Parkinson Disease Psychosis. J Am Med Dir Assoc. 2015 Oct 1;16(10):898.e1-7. doi: 10.1016/j.jamda.2015.06.021. Epub 2015 Aug 1.

MeSH Terms

Interventions

pimavanserin

Results Point of Contact

Title
Sr. Dir. Medical Information and Medical Communications
Organization
ACADIA Pharmaceuticals Inc.

Publication Agreements

PI is Sponsor Employee
No
Restriction Type
OTHER
Restrictive Agreement
Yes

Study Design

Study Type
interventional
Phase
phase 3
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 26, 2007

First Posted

October 29, 2007

Study Start

July 1, 2007

Primary Completion

May 30, 2018

Study Completion

May 30, 2018

Last Updated

June 24, 2019

Results First Posted

June 24, 2019

Record last verified: 2019-05

Data Sharing

IPD Sharing
Will not share

Locations